Telix Pharmaceuticals (NASDAQ:TLX) Sets New 1-Year Low – Here’s What Happened

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s share price hit a new 52-week low on Thursday . The stock traded as low as $8.83 and last traded at $8.83, with a volume of 41800 shares changing hands. The stock had previously closed at $9.04.

Analyst Ratings Changes

TLX has been the topic of a number of analyst reports. Citigroup initiated coverage on Telix Pharmaceuticals in a research report on Thursday, September 18th. They set a “buy” rating and a $22.00 target price on the stock. Canaccord Genuity Group upgraded Telix Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 6th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Telix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Telix Pharmaceuticals Stock Up 1.6%

The business’s fifty day simple moving average is $10.07 and its 200 day simple moving average is $12.96.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers boosted its stake in Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after acquiring an additional 1,392 shares during the period. Private Advisor Group LLC bought a new stake in shares of Telix Pharmaceuticals in the 1st quarter worth approximately $170,000. IHT Wealth Management LLC bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth approximately $213,000. Blair William & Co. IL acquired a new position in Telix Pharmaceuticals during the 2nd quarter valued at approximately $217,000. Finally, JPMorgan Chase & Co. bought a new position in Telix Pharmaceuticals during the 3rd quarter worth $243,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.